Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial

被引：0
|
作者：
Weisel, K. [1 ]
Einsele, H. [2 ]
Goldschmidt, H. [3 ,4 ]
Delforge, M. [5 ]
San Miguel, J. [6 ]
Bertin, K. B. [7 ]
Tahir, M. [7 ]
Lewis, H. [8 ]
Wang, J. [9 ]
Braverman, J. [9 ]
Campbell, T. B. [9 ]
Munshi, N. [10 ,11 ,12 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Hosp Wurzburg, Wurzburg, Germany
[3] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Univ Hosp Leuven, Leuven, Belgium
[6] Univ Navarra Clin, Pamplona, Spain
[7] ICON Plc, San Francisco, CA USA
[8] ICON Plc, London, England
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[12] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [21] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
    Albert, Oriol
    Jesus, San-Miguel
    Ankit, Kansagra
    Deepu, Madduri
    Nina, Shah
    Philippe, Moreau
    Ibrahim, Yakoub-Agha
    Michel, Delforge
    Michele, Cavo
    Hermann, Einsele
    Hartmut, Goldschmidt
    Katja, Weisel
    Alessandro, Rambaldi
    Donna, Reece
    Paula, Rodriguez-Otero
    Fabio, Petrocca
    Jamie, Connarn N.
    Payal, Patel
    Huang Liping
    Timothy, Campbell B.
    Kristen, Hege
    Nikhil, Munshi C.
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
  • [22] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
    Goldschmidt, Hartmut
    Raje, Noopur
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil
    Moreau, Philippe
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy
    San-Miguel, Jesus
    Reece, Donna
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
  • [23] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
    Kansagra, Ankit
    Lin, Yi
    Berdeja, Jesus G.
    Shah, Nina
    Oriol, Albert
    Yakoub-Agha, Ibrahim
    Einsele, Hermann
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Rowe, Everton
    Wang, Julie
    Agarwal, Amit
    Campbell, Timothy B.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [24] KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Truppel-Hartmann, Anna
    Fei, Yizhou
    Wortman-Vayn, Honeylet
    Shelat, Suresh
    Novick, Steven
    Shah, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [26] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [27] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [28] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [29] Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
    Ayers, Dieter
    Cope, Shannon
    Dhanda, Devender S.
    Towle, Kevin
    Mojebi, Ali
    Delforge, Michel
    Rodriguez-Otero, Paula
    Trudel, Suzanne
    Weisel, Katja
    Zamagni, Elena
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S139 - S140
  • [30] KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Green, Damian J.
    Jagannath, Sundar
    Lonial, Sagar
    Gipson, Adrianna
    Caia, Andrea
    Martin, Nathan
    Yang, Zhihong
    Pittari, Gianfranco
    Mateos, Maria-Victoria
    BLOOD, 2021, 138
12345